Podcasts about zepbound

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?Produced and presented by Sam FenwickIf you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukBusiness Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Photo: A man gets his waist measured. Credit: Getty Images)

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real cost of obesity drugs in the U.S. healthcare system.How much do GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro actually cost? Are they cost-effective in the long term? And can insurers and employers afford to provide them to millions of Americans living with obesity?If you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukProduced and presented by Sam Fenwick.Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small startup stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the weight-loss drug revolution, the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs.These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Picture: Person standing on weighing scales. Credit: Press Association)

You can listen to the first episode of this three-part series here. GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one. Chris Hannay, The Globe's business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we'll explore access to these drugs with The Globe's health reporter Kelly Grant on who gets their GLP-1 covered by their insurance – and who doesn't. Plus, Globe audio producer Kasia Mychajlowycz leads us on a journey to understand just how the virtual pharmacies advertised all over her social media feed are vetting people who want Ozempic prescriptions. The next episode and final episode of Skinny, Inc. is next Monday, March 9. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Kym Whitley is an unmissable force, a comedic genius who lights up every screen and stage she graces, balancing a thriving career, the intricate journey of personal transformation, and the deeply personal mission of motherhood. She's not just breaking stigmas; she's building bridges of understanding, inspiring millions with her candor, courage, and hilarious authenticity, making her a truly unforgettable voice for change and joy.Takeaways:Finding Your "Because": Your deepest purpose is often inherent, a natural gift meant to be shared, whether it's bringing laughter or fostering connection.Motherhood as a Catalyst for Growth: Becoming a parent intensifies life's demands, but it also provides a profound opportunity for personal growth and a re-evaluation of priorities.Breaking the Stigma Around Obesity: Approaching obesity as a chronic disease and utilizing available tools, like Zepbound alongside diet and exercise, can be a crucial step towards health without shame.Sound Bytes:"My because is because that is how I was made.""Motherhood means you gotta grow up. That was like, this is not a game.""Do you know, Mick, I didn't realize that obesity is a disease. Did you know that?"Connect & Discover Kym:Instagram: @kymwhitleyFacebook: @kymwhitleyX: @kymwhitleyWebsite: iamkymwhitley.comZepbound: zepbound.lilly.comLilly: lillydirect

What if the reason you’re not healing isn’t that you need another diagnosis? 0:08 It’s that your cells aren’t receiving the right signals. Because the body doesn’t run on diagnosis, it runs on 0:16 communication. And peptides are one of the most powerful, most misunderstood 0:21 tools we have for cellular signaling, immune balance, tissue repair, gut 0:27 lining support, metabolic control, brain signaling, sleep cycles, and even sexual 0:35 wellness. Today, I’m going to do what most people won’t. Define peptides in 0:41 plain English for you. break them into categories by what they’re best at and 0:47 tell you which ones are FDA approved on the list and which ones are commonly 0:53 used off label or investigational with the evidence that actually says these 1:00 work. This is going to be a powerful episode and if you’ve ever felt like you’re hearing hype without clarity, 1:07 this one’s for you. So, as usual, grab your cup of coffee or tea and settle in 1:13 as we talk about peptides that can fit into your healing journey. We’re going 1:19 to have a short word from our sponsor. You know, we got to do that. That’s how we stay on the air here. So, we will be 1:26 right back after this. Did you know sweating can literally heal your cells? 1:32I nfrared saunas don’t just relax you. They detox your body, balance hormones, 1:37 and boost mitochondrial energy. I’m obsessed with my health tech sauna. And 1:42 right now, you can save $500 with my code at healthtechalth.com/drmuthqen25. 1:54 All right, here we go, guys. I am excited to dive into peptides with you. 2:00 So understanding peptides is foundational, right? And I’ve been 2:06 studying peptides now for about nine years. Um, and I find that they are 2:13 incredible. Um, so I want to break down for you what peptides actually are, what 2:19 they do, and some of the top peptides that are available today, and how they 2:25 can be utilized. Because I think it’s really important. And I think it’s it’s there’s a lot of confusion out there about what these things actually are and 2:32 are they safe? Are they not? When do we use them? What’s the science behind them? So, we’re going to dive in and 2:38 we’re going to talk about all things peptides. So, let’s get ready here. Here we go. So, peptides are short chains of 2:45 amino acids and they typically range anywhere from 2 to 50 amino acids and 2:51 they’re linked by peptide bonds. So think of them as the superglue that holds the amino acids together. They sit 2:58 between the amino acids and they are full proteins in terms of their size and 3:04 their complex structure. And what makes peptides particularly interesting in 3:10 medicine is their role as signaling molecules. They’re essentially the 3:15 body’s text messages carrying specific instructions to cells and tissues. And 3:21 unlike our proteins which often serve as structural roles or act as enzymes, 3:28 peptides typically function as hormones, neurotransmitters and growth factors and 3:33 they bind to specific receptors on the cell’s surfaces or within the cells and 3:39 they trigger this effect. It’s like a cascade effect of a biochemical reaction 3:45 that ultimately changes the cellular behavior. So basically, it’s changing 3:50 the way the body’s cell structure acts. And this is why peptides can be so 3:56 incredibly powerful and therapeutic when you introduce the right peptide signal. 4:02 Now, you could theoretically redirect cellular processes toward healing, 4:07 towards metabolism, immune balance, tissue repair. Any of those things can 4:14 be manipulated to do a certain thing once we add the peptide. The challenge 4:19 in peptide medicine though lies in distinguishing between those peptides that have been rigorously studied, 4:26 proven safe and effective and approved by regulatory bodies like the FDA versus 4:31 those that exist in what we call the gray zone of a promising clinical data. 4:36 But they really lack human validation so far. And this distinction is critical because the presence of a plausible 4:43 mechanism does not guarantee safety or efficacy in living humans. So, this is 4:50 really important and we’re going to dive in and look at some of the research on all of these different peptides that are 4:56 available and I’m excited to say there’s some amazing peptides being studied right now that unfortunately are not 5:01 available. But I can’t wait to see them hit the market for us because it is going to be a gamecher as far as health 5:09 and longevity. So there is a quality control issue and there is a hidden 5:14 variable in peptide medicine with this and it’s one of the most underappreciated aspects of peptide 5:21 therapy particularly for non-FDA approved peptides. It’s quality control. 5:26 When we discuss pharmaceutical medicines, we take for granted that the pill contains what the label says. Not 5:32 always true depending on where it comes from. You guys, if you’ve heard my episodes before talk about how many of our medications are made in China and 5:41 have been contaminated with other things, you will realize that that is not always true. So, just because it has 5:48 the FDA stamp of approval on the medication, it still does not necessarily mean it’s safe and we still 5:54 need to do our homework on it. So, sorry for digressing on you guys, but you know, when we get a medication, we we 6:00 think that what the amount says is what is there, doesn’t have contaminants, it’s manufactured with good 6:06 manufacturing practices. You’ll see that listed as GMP on the bottle, and it’s been stored properly, it’s been 6:12 maintained stable, and with research peptides and compounded formulations, 6:17 none of this can be assumed. So, I will share a story with you. There was a gentleman that was purchasing these 6:24 peptides online from a research facility and um did not know that they were 6:30 coming from China and he was ordering a particular growth hormone peptide and 6:35 after a little while he had he had done fine for the few first few bottles. After a little while he started having 6:42 some complications. He started getting really irritable and angry and ragy and 6:47 he didn’t quite know what was going on. And so he decided to go get some testing done. He had some blood testing done and 6:53 his testosterone level was over 5,000. So for those of you who know what testosterone level should be for a guy, 7:00 they really shouldn’t be any higher than about 1,00200 would be absolute max that we’d want to see. Now he was taking 7:06 testosterone but not to that degree. And prior to adding this peptide, his 7:12 testosterone was very stable. What they ended up finding out was the peptide that he was getting, whoever was 7:18 manufacturing it added testosterone to the peptide. They felt like if if it had growth hormone, that was great, but if 7:25 it had growth hormone and tes testosterone, all the better. And he didn’t know that. And this is the 7:31 problem that we can have with peptides if you don’t source them properly. if you’re not working with somebody that 7:37 knows how to source them and can prove that they are what they say they are. Um, I’m sure there’s a whole bunch of 7:42 studies out there too of people getting these peptides and paying hundreds of thousands of dollars for them over their 7:48 lifetime and finding out they were nothing more than just sterile water. So, you really do need to be careful 7:53 with your quality control. Now, this kind of leads us right into the next topic that we’re going to talk about and that’s the manufacturing question, 8:00 right? The FDA approved peptides are manufactured in facilities subject to 8:05 the FDA inspection rules following our GMP regulations and these facilities 8:11 must validate their manufacturing process, demonstrate consistency batch to batch, test for purity and potency. 8:18 They need to test for bacterial endotoxins and sterility and they need to maintain detailed records. So, when a 8:25 pharmaceutical company submits a drug application, the FDA inspects the manufacturing facility as part of the 8:32 approval process. If you’re getting peptides from a different country, none of that is happening. And there are some 8:38 ways for us to determine if that is what you’re getting. Typically, the rule of thumb is if your peptides are coming 8:44 with a different colored top, every one of them has a different colored top. Those are typically being sourced out of 8:49 China. I wouldn’t say that’s 100% but that’s kind of the rule of thumb that people follow. So compoundingies these 8:56 are thearmacies that make our bio identical hormones. They can make medications in any dose or strength or 9:02 route. There are thousands of them in every not that not in every state but 9:08 there are thousands of them around the country right now. So these compoundingies are registered as 503A 9:15 facilities. They do traditional compounding for individual prescriptions, right? Like they can make 9:20 thyroid, they can make LDN, they can make estrogen. You can also have a 503b 9:27 facility, which is an outsourcing facility. And these companies produce larger batches of products. They’re they 9:34 have some oversight, but they’re less stringent than for FDA approved 9:40 manufacturers. And state boards of pharmacy regulate a 503A pharmacy. And 9:45 the FDA can inspect the 503b facility, but doesn’t preapprove any of their 9:52 compounding products. So, they can inspect it, but they don’t approve them. So, research chemicals and these 9:58 suppliers operate essentially with no oversight. They explicitly market products for research use only, not for 10:06 human consumption to avoid FDA regulation. If they put that on their 10:12 product, they don’t have to comply to what the FDA is saying. And there is no required manufacturing strategies or 10:19 standards, no required testing, no required sterility assurance, and no enforcement mechanisms if products are 10:26 mislabeled or contaminated. So basically, they don’t have the liability, but that doesn’t mean that 10:31 all of them are badies or bad suppliers. It just means they don’t have to comply 10:37 to the FDA rules. Now, there are many of these companies that I’ve seen and I’ve talked to that do do a lot of this. They 10:44 do test their product for sterility. They do test their product to make sure it is what it says it is. They don’t 10:51 have to, but they do. So, if you’re going to decide to use a company that 10:56 has research only, not for human consumption, at least ask for their 11:02 proof of testing so that you know that the product you’re getting is what it says it is and that it’s clean. Because 11:08 this is where we run into the problem is in purity. So in purity peptide 11:13 synthesis can produce not just the targeted peptide but also related 11:19 peptides with deletions, substitutions, truncations or truncations of amino 11:25 acids. Sorry. And this high performance liquid we call it uh chromatography can 11:30 separate these related impurities and quality and quantify the actual target 11:35 of the peptide content. So a certificate of analysis is what you want to ask these companies for. This shows the HPLC 11:44 the testing mechanism with greater than 95% or ideally 98% purity which 11:51 indicates a higher quality product. So this certificate of analysis can be fabricated may not represent the 11:57 specific batch being sold. It happens. We need to know not everybody is honest. Not everybody, you know, does what they 12:03 say and it does what’s right. But at least you at least they’re giving you something and you have some security. 12:10 and then choose a company that was referred to by someone else that has done some homework as well. In in 12:16 commercial research, there’s independent testing and they research peptides and this has been really shocking 12:23 variability that they’ve seen. Some products contain 50% or less of the 12:29 claimed peptide and some contained primarily degradation of the product or manufacturing impurities and some 12:36 contained bacterial endotoxins at levels that could cause fever and systemic 12:42 inflammation if it was truly injected. And I would also worry with some of those problems, you know, depending on 12:48 what impurity or bacterial endotoxin was there. If you’re using a product to boost your immune system and your immune 12:54 system is already compromised, these bacterial endotoxins can actually make you sicker instead of what you want it 13:02 to do, which is making you better. So, sterility is always an issue with anything that is manufactured, 13:08 especially things that we’re doing as an injection. Peptides are intended for injection. They must be sterile. They 13:16 must be kept safe. And pharmaceutical manufacturers conduct this sterility testing on every batch. 13:22 Compoundingarmacies should conduct sterility testing particularly for high-risisk compounded 13:28 sterile preparations and research chemical suppliers may or may not conduct any testing. So injecting 13:35 non-sterile material can cause local infections, abscesses at the injection 13:41 site and or if the bacteria enters the bloodstream could potentially be 13:46 life-threatening and you could have sepsis. Now, excuse me. We saw this 13:52 happen in a compounding pharmacy uh gosh, it’s probably been 10 years ago 13:57 now, I think. um they unfortunately had a strep uh contamination in their 14:03 product and they weren’t testing it. It was a large compounding pharmacy out of Florida and they were making products 14:08 that were being injected into the joints and um these people got very very sick 14:14 and some of them died and um some of them got very very injured by this uh 14:21 complication that happened. So it’s not like this doesn’t happen. It does, but it doesn’t happen often. And that’s what 14:28 we have to know about. And so, when we’re talking with you guys about storage and stability, it’s really 14:34 important to make sure you maintain your peptides well. So, many peptides are unstable at room temperature. They 14:41 require refrigeration or freezing. We tell everyone to make sure you’re refrigerating your peptides. That way, 14:48 there’s no question about it. when it stays cold um it prevents or slows down 14:54 the process of uh bacteria growing in it. So some of these peptides actually 14:59 degrade very rapidly in the solution and they must be reconstituted immediately before use and reconstitution of the 15:07 peptides really has limited stability often just days to weeks not months. So 15:13 improper storage, temperature, um changes during shipping or prolonged 15:19 storage of a reconstituted product can lead to degradation into inactivity or 15:25 potentially even a harmful breakdown of the product itself. So if you have a product that’s been sitting in your 15:30 refrigerator for a month or two months or 3 months or 6 months, just throw it away. It’s not going to be any good. 15:37 you’re not going to actually get the peptide and the uh potency that you’re looking for anyway out of it and the 15:44 potential of you introducing an endotoxin, a bacterial endotoxin is quite high at that point. So you just 15:50 really don’t want to take the risk, excuse me. So what practitioners, what 15:56 should we do and what should patients do? Well, for any peptide therapy, we 16:03 want to source our verification. know where the peptide product comes from. Is 16:08 it an FDA approved product? Is it a 503b compounding? A research chemical 16:14 supplier? Is there a certificate of analysis? Request and review this COA. 16:20 And you want it to show purity greater than 95% but ideally greater than 98%. 16:27 You want that identity be identity to be confirmed by mass spectromedy. Uh 16:33 sterility testing should be done. Bacterial endotoxin testing should be done. Batch number matching of the 16:39 product that you received should be done. Proper storage. You want to know that this has been refrigerated or 16:46 frozen as directed once it’s been mixed. Look at the expiration dates for reconstituting your peptides. Track that 16:53 reconstitution date and discarded accordingly like we just talked about. Monitor for your adverse effects. Even 17:01 with the perfect quality control, monitoring for adverse effects is essential with questionable quality and 17:08 vigilance is really critical here. I know it’s frustrating for a lot of patients when they have to get several 17:15 bottles and they only last a week or two. right here, you guys. This is why 17:21 they only last a short period of time because once they’re mixed, they start 17:26 to degrade and they won’t be good and you won’t get the benefit from it. So, 17:31 it’s really important with these research peptides specifically, practitioners should recognize that all 17:38 recommending products without quality assurance violates the fundamental medical principle of first do no harm. 17:45 If a patient is determined to use research peptides despite counseling, providing guidance on quality 17:52 verification, requesting those COAs, using pharmaceutical grade sources when available, proper testing, this all 17:59 reduces harm, but doesn’t constitute necessarily that recommendation. Now, 18:06 that being said, today it’s very difficult to find peptides by the compoundingies because of what the FDA 18:13 has done. So most of the peptides that are available to us have been labeled 18:18 not for human consumption, not because they’re not good products, but because 18:25 of what the FDA did. And this is how these companies have been able to 18:31 continue to provide peptides to the medical community. And if you know you 18:36 have a good company, then you’re, you know, you’re still taking the risk, right? But at the end of the day, the 18:42 reason they’re doing that is to protect themselves from the FDA, from liability. Um, so just kind of know that there is 18:50 some talk in the community with um Bobby Kennedy that this is going to change and 18:55 they are going to bring peptides back to the compounding pharmacies. Now, we don’t know which ones they’re going to 19:01 bring back. Uh, will it be all of them? Will it just be some of them? What’s going to happen here? Um, is it going to 19:07 go to the pharmaceutical companies like our GLP1s did? We don’t know what that’s going to look like quite yet. Um, but it 19:14 is coming and that is positive news. So, let’s talk now about FDA approved 19:21 peptide medications. So, this is the metabolic revolution, right? GLP1 19:28 and our dual increeting agonists. This is an exciting time. GLP-1s are amazing. 19:35 Um, a lot of people are skeptical, a lot of people love them, a lot of people hate them. Whichever side of the fence 19:42 that you’re on, I understand. But I want to talk about the science of it today 19:48 and what it actually means for people. So, the story of GLP1 glucagon like 19:54 peptide one represents one of the most significant advances in metabolic 19:59 medicine in the past several decades. GLP-1 is an accretin hormone. It’s 20:05 gutder derived peptide that potentiates insulin secretion in response to food 20:11 intake. And the body naturally produces GLP-1 in the intestinal L cells, but it 20:17 rapidly degraded by the enzyme DPP4 giving it a halflife of only about 2 20:24 minutes. So this rapid breakdown made in therapeutically impractical until 20:31 research was developed and modified the analoges that resist the enzyme degradation. So for those people who 20:39 never feel full when they’re eating, never feel satisfied when they’re done, this is because their body is either not 20:46 producing enough GLP1 or it’s not getting the signal right. And this is a 20:51 leptin issue. This is an insulin issue. It’s a GLP-1 issue. It’s a complicated 20:56 issue. This is not anything that the person is doing wrong. It’s what is happening to their body. And so GLP1s 21:03 have really revolutionized this. So one particular GLP-1 that we have is 21:09 semiglutide. And this GLP-1 agonist is what changed everything in the world of 21:16 metabolic medicine. Semiglutide is marketed as ompic for type 2 diabetes 21:23 and it’s marketed as WGOI for chronic weight management. It is a modified 21:29 GLP-1 analog with 95 or sorry 94% amino acid sequence uh homology to human 21:37 GLP-1. So it means that it’s it’s just like our own GLP-1 that we make. This 21:42 modification includes specific amino acid substitutions and the addition of C18 21:50 a fatty acid chain which allows the peptide to bind to albumin. Now this 21:56 albumin binding dramatically extends the half-life to approximately one week 22:01 enabling one weekly dosing which is a major advantage over the earlier GLP-1 22:07 agonists that require daily or twice daily injections. The mechanism by which 22:13 semiglutide works is multiaceted. At the pancreatin level, it binds to GLP-1 22:20 receptors on the pancreatic beta cells enhancing glucose depending sorry 22:27 enhancing glucose dependent insulin secretion. This glucose dependency is 22:33 crucial. It means the peptide only stimulates insulin release when blood glucose is elevated. This dramatically 22:41 reduces the hypoglycemic risk compared to insulin or even uh sulfuras. 22:47 Simultaneously semiglutide suppresses glucagon secretion from pancreatic alpha 22:53 cells further improving glycemic control. This is really amazing because 23:00 over the years when we’ve used insulin, which is also a peptide by the way, you 23:05 had to dose it just right because if you didn’t, you would produce so much insulin that it would crash the blood 23:12 sugar and then somebody would have too low of a blood sugar. They’d be hypoglycemic and they’d have to eat more 23:18 sugar and then they’d have to modify the insulin again and the person would be going up and down, up and down, up and 23:24 down all day long. And that created a lot of problems for people and so this 23:30 helps to stabilize that so it is not such an intense change. Now in the GI 23:36 tract semiglutide delays the gastric emptying particularly pronounced during 23:41 the initial weeks of therapy. This slowing of the gastric emptying contributes to the sensation of being 23:48 full and early satiety that patients often describe. However, this effect 23:54 tends to attend to weight over time as the body adapts through the appetite 24:00 suppressing effects generally persist through central mechanisms. So, when we 24:05 talk about what is actually happening, we’re slowing that digestive process down. That’s why people aren’t so 24:11 hungry. It’s why they’re not eating so much. This is why people can develop constipation with these products because 24:17 it’s slowing the body’s digestive tract down. Now some people will call this 24:22 gastroparesis. Um gastroparesis is actually different. 24:28 It is when we lose control over what’s happening in the in the colon like the 24:34 nerves and things like that just stop working. I have never seen that with the GLP1s that we prescribe in micro doing. 24:42 um it’s been documented. It can happen, but again it a lot of it is dosing and a 24:48 lot of it is staying on top of your client and what’s happening and what’s going on and what you’re doing and making sure that they do have good 24:54 motility still. So a lot of these things can be mitigated if you have problems 24:59 with them. Now one of the most profound effects of semiglutide occur in the 25:05 central nervous system. GLP-1 receptors are widely distributed in the brain 25:10 particularly in the hypothalamus and the brain stem area where we are involved in 25:15 appetite regulation. So when when wilding and colleagues published their 25:20 landmark step one trial in the New England Journal of Medicine in 2021, 25:25 they demonstrated that participants receiving 2.4 4 milligrams of semiglutide weekly achieved an average 25:32 weight loss of 14.9% of their body weight over 68 weeks. Now, I want you 25:39 guys to really understand this. We’re talking roughly 15% body weight loss 25:45 over a year, longer than a year. 52 weeks is a year, right? This is 68 25:50 weeks. So, it took longer for them to lose. We’re not talking about giving 25:55 somebody a dose to lose 15% of their body mass in a month or two. That that 26:01 is not healthy for any of us. That is not what we’re talking about doing here. Now, they compared this to placebo and 26:08 the placebo was only 2.4%. So, that is a significant difference. 26:14 And even beyond the numbers, patients reported something very qualitatively different, a reduction in what’s now 26:21 called food noise. Everybody knows what food noise is. We’ve talked about this long before GLP1. It’s that craving. 26:28 It’s that part of your brain that just keeps thinking about I want to eat something. You know, that was actually 26:34 reduced and they didn’t expect to see that happen. Now, this refers to the constant mental preoccupation with food, 26:42 the intrusive thoughts about eating, the difficulty in feeling satisfied. Semi-glutide appears to appears to 26:49 modulate reward pathways in the misolyic system reducing hedonic eating and food 26:57 cravings. Now there are also great cardiovascular effects of semiglutide 27:02 that extend beyond weight loss. Uh the sustained six and select trials 27:07 demonstrated significant reductions in major adverse cardiovascular events uh 27:14 mace in high-risisk populations. The select trial published in 2023 showed 27:20 that semiglutide reduced cardiovascular death, non-fatal myioardial inffection 27:25 and non-fatal stroke by 20% in adults with overweight or obesity and 27:31 established cardiovascular disease but without diabetes. So this suggests that 27:37 mechanisms beyond glucose control and weight loss possibly including 27:42 anti-inflammatory effects, improvements in endothelial function and favorable 27:47 changes to lipid profiles. Now I will tell you the clients that I work with that are on GLP1, 27:53 they will tell you that their inflammation has been significantly reduced. We are also seeing really 28:00 amazing results in lipid profiles. um part of its weight loss, but there is a 28:06 component to this that is lowering the triglyceride levels because it’s related to sugar and how the body’s processing 28:11 it. And we’re seeing better profiles, less need for statins as a result of 28:17 that. If if you want to listen to my episode on statins, I have one on that. Uh they are not my favorite medication. 28:24 I think it’s overprescribed and overused um and not really affecting or 28:29 addressing the problem. So these things can really be helpful. There’s also some 28:34 uh ramblings going on with GLP-1s saying that they may be able to help with 28:40 addiction in the future because of where they’re finding it affecting the brain and how it affects the food noise and 28:47 the cravings that we have for food and the addiction for food. Could it potentially help with other addictions 28:53 down the road? We’ll have to wait and see on that one. So semiglutide’s FDA prescribing information also includes a 29:00 box uh boxed warning about thyroid sea cell tumors. So in rodent studies 29:06 semiglutide caused dose dependent and treatment duration dependent sea cell 29:12 tumors at clinically relevant exposures. So while it’s unknown whether or not 29:17 semiglutide causes uh thyroid cancer tumors in humans and the rodent thyroid biology 29:26 differs significantly from humans, the drug is contraindicated in patients with a personal or family history of 29:33 medillary thyroid carcinoma or in patients with multiple endocrine neopl neoplasia syndrome type two. it is 29:42 uh contraindicated for safety effects with that. Um I have seen endocrinologists okay GLP1s to be used 29:50 in patients who’ve had other forms of thyroid cancer just not the meillary 29:55 thyroid cancer. So there is possibility there. Now the most common side effects 30:00 are gastrointestinal. It’s nausea affects about 20 to 44% of patients 30:06 depending on the formulation with diarrhea, vomiting, constipation, abdominal pain, and also frequently 30:13 reported in clinical trials. I see this in my clinic, too, especially dose dependent. Um, and it happens early on 30:20 when you’re first starting the medication, but seems to settle out over time. The one that I would add to this 30:26 that I don’t think they have on here is an increase in acid reflux. We also see that quite often uh especially in people 30:33 who suffer with acid reflux to begin with. Now these effects are typically most 30:40 pronounced during the escalation and they like I said often improve over time 30:45 but more serious but less common adverse effects include acute pancreatitis. 30:51 The medication needs to be discontinued immediately if this is confirmed. You can see some diabetic retinopathy 30:57 complications in patients with pre-existing retinopathy and acute kidney injury. Um, this usually happens 31:05 secondarily to dehydration from the GI effects. There are some gallbladder disease um that can occur and people who 31:13 have a sensitive gallbladder will describe uh discomfort with that. I’ve 31:18 even seen some people who’ve had their gallbladder out on GLP1s at the higher doses complain of similar pain that they 31:25 used to have when their gallbladder was in. So, really important to just kind of monitor these symptoms and work closely 31:32 with somebody that understands them and can be on top of them quite quickly if this happens. Excuse me. From an 31:39 integrative medicine perspective, semiglutide really represents a powerful tool, but it’s not a standalone 31:46 solution. Remember, the medication addresses one aspect of the metabolic dysfunction, the signaling systems 31:53 controlling appetite and glucose homeostasis, but it doesn’t address the root cause that led to the metabolic 32:00 disease in the first place. Patients who rely solely on the medication without addressing the ultrarocessed food 32:07 consumption, the ccadian disruptions, the chronic stress, the sleep apnea, or 32:12 underlying hormonal imbalances often experience weight regain when the medication is discontinued. 32:20 The drug is also not a substitute for addressing the emotional and psychological drivers of eating 32:26 behavior, including the unresolved trauma that may manifest as emotional eating. I think this is really important 32:33 because we don’t address the trauma issue enough with clients and we need to 32:38 be looking at that. There is a huge trauma effect out there these days that is I don’t want to say leading to or 32:45 causing but it is definitely contributing to chronic illness and it’s not being talked about enough. So we 32:52 really need to be talking about this and addressing this trauma aspect. Now the next GLP that one that I want to talk 32:59 about is trespathide. This is a dual agonist. It takes center stage. It is my 33:05 favorite GLP one. Trisepatide is marketed as Mangjaro for type 2 diabetes 33:11 and Zepbound for chronic weight management and it represents the next 33:16 evolution in increantbased therapy. This is a dual agonist a 39 amino acid 33:23 synthetic peptide structurally based on the human glucose dependent insulin tropic peptide so GIP sequence but 33:31 modified to activate both the GIP receptors and the GLP1 receptors. So the 33:37 addition of the GI GIP agonism to the GLP1 agonism appears to create this 33:46 synergistic effect that goes beyond simply adding the two mechanisms together. So the GIP like GLP-1 is an 33:55 increant hormone secreted by what is called the K cells in response to nutrient intake. It enhances glucose 34:02 dependent insulin secretion but it also effects on atapost tissue metabolism 34:09 potentially improving the insulin sensitivity in fat cells and influencing 34:14 how the body stores and metabolizes fat. So some research suggests that GIP may 34:20 also have effects on energy expenditure though this remains an area of 34:26 investigation. So basically what we’re saying is this drug may actually help 34:32 people who are insulin resistant or insulin sensitive, not just somebody who 34:38 has problems with glucose control. So, this is super exciting because it opens 34:43 up the door for all of these people for decades that we’ve been trying to manage with insulin resistance and trying to 34:50 prevent diabetes and honestly most of the time have been unsuccessful 34:56 unless you can keep your diet at 50 grams of carbs or less a day, which is extremely difficult. Um, and take some 35:04 supplements that may or may not work and or take some metformin that may or may not help. this drug actually really 35:11opens that up and helps in that capacity. So there was a clinical trial 35:17 called the surmount clinical trial which demonstrated that trespathide produces 35:22 even more substantial weight loss than semiglutide. In the surerount one trial published by uh J tree I might have said 35:31 that wrong. I apologize if I slaughtered your name and colleagues in the New York England Journal of Medicine in 2022. 35:38 Participants receiving the highest dose of trespide, which is 15 milligrams, achieved an average weight loss of 20.9% 35:47 of their body weight over 72 weeks, compared to 3.1% with placebo. This 35:54 level of weight loss approaches what’s typically only seen in beriatric surgery. So, this is amazing because if 36:02 this medication works and we don’t have to do beriatric surgery, stomach stapling basically, um, oh my gosh, it’s 36:11 amazing. There are so many complications and risks that go with stomach stapling and the different procedures that they 36:17 do these days. People don’t absorb their nutrients properly. They have to do liquid nutrients. It’s very complicated. 36:24 It’s very challenging. Many of these people gain their weight back. Um, and 36:30 this procedure is not fun to go through. So, if we could change that and change 36:35 the lives of people who’ve really been struggling, it is amazing. And I will tell you that I have seen this work. I 36:42 have seen people lose 100 150 pounds on these medications over a year or two 36:50 period of time. It is definitely slower than beriatric surgery on some standpoints, but that is okay. You don’t 36:56 want that rapid weight loss. It’s not good for you. It’s not healthy for you. It doesn’t look well. You know, we want 37:03 to do this safely and effectively in the best way that we can possibly do that for you. Now, the adverse effect profile 37:10 is similar to semiglutide. It’s dominated by gastrointestinal effects. 37:15 Nausea, diarrhea, decreased appetite, vomiting, constipation. These were all commonly reported in the surmount 37:22 trials. And like semiglutide, tricepide carries a blackbox warning regarding the 37:27 thyroid sea cell tumors based on the rodent data and it shares the same contra indications in patients with a 37:34 family history of thyroid cancer and men too. So the mechanism behind why 37:40 tepatide often produces more substantial weight loss than GLP-1. The agonism 37:45 alone remains under investigation, but it may relate to the complimentary effects on the different aspects of 37:51 energy homeostasis or to GIP’s effects on atapost tissue and potentially on 37:58 central central nervous system pathways that GLP1 alone doesn’t fully address. 38:03 Now patients often report even more profound reductions in food noise with tricepide compared to GLP1 and uh sorry 38:12 GLP1 the agonists through this is anecdotal and hasn’t been regularly 38:17 quantified in quality studies. So I’ve done both uh personally and in my 38:22 practice. I really like trespide better than semiglutide. For me I had too many side effects with semiglutide. uh I had 38:30 less side effects with trespathide. I also plateaued on semiglutide which I 38:35 didn’t really care for. And with Tresepide, I haven’t plateaued and I’ve been able 38:42 to lose about 25 pounds in um a year and a half and I’ve been able to maintain 38:49 that. Um and I continued to use it because I do have a strong family history of cardiovascular disease. And 38:56 if this could help me so that I don’t follow my family lineage with cardiovascular disease, I am all for 39:03 trying to do that. I’ve watched too many of my family members suffer from this. I’ve lost my dad at a very young age. I 39:09 lost my grandfather at a young age to it. All of their brothers to this. And I don’t want to be that same person. So 39:16 that is why I chose to do that. And I think it’s really important for us to take a look at that and understand that. 39:24 Now, I know this has been a really long podcast and I don’t typically do podcasts this long. I have a whole host 39:31 of information on additional peptides. So, I’m going to break this up for you 39:36 guys and I’m going to do another episode and we’re going to pick up where we left off here with these peptides so that we 39:43 can actually start to dive into different peptides as well. So, check 39:48 out my next podcast show when we’re going to dive into the peptides that 39:54 talk about sexual wellness, immune function, and all the other cool things 39:59 that we can do with peptides. So until then, remember to like, share, and 40:04 subscribe. It really helps us get out to other people and share our information, 40:10 and join us for our next episode as we continue the talk about peptides. 40:15 Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and 40:21 information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its 40:28 management, or our partners. Each affiliate, sponsor, and partner is an 40:34 independent entity with its own perspectives. Today’s content is provided forformational and educational 40:40 purposes only and should not be considered specific advice, whether financial, medical, or legal. While we 40:48 strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique 40:56 circumstances. We encourage you to consult with a qualified professional to address your 41:01 individual needs. Your use of information from this broadcast is entirely at your own risk. By continuing 41:08 to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its 41:14 associates harmless from any claims or damages arising from the use of this 41:20 content. We may update this disclaimer at any time and changes will take effect 41:26 immediately upon posting or broadcast. Thank you for tuning in. We hope you 41:31 find this episode both insightful and thought-provoking. Listener discretion 41:36 is advised.The post Episode 256 – How Peptides Work, Benefits, and FDA-Approved vs Off-Label Use Explained first appeared on Let's Talk Wellness Now.

On this week's episode, Tess Cameron, Josh Schimmer, Brian Skorney, and special guest Adam Feuerstein kick off with regulatory updates, including the FDA's rejection of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo -- a therapy that should have been approvable. The co-hosts then highlight ongoing inconsistencies at the agency and the challenge it creates for investors and companies as the regulatory goal posts continue to shift. Next, they discuss a New York Post editorial from the Alliance for Regenerative Medicine CEO Tim Hunt, who outlined how last‑minute reversals on rare disease and CGT approvals are leaving patients and biotech companies in limbo. The conversation then shifts to deals, including Gilead's $7.8B acquisition of Arcellx for full control of anito-cel for relapsed/refractory multiple myeloma, and Vir's pivot to oncology through a $1.7B collaboration with Astellas. In data news, the co-hosts cover CagriSema's head-to-head trial results against Lilly's Zepbound, Gossamer Bio's lung disease drug, seralutinib, which did not meet the primary endpoint in its Phase 3 pulmonary arterial hypertension study, and Palvella Therapeutics' positive topline results from the Phase 3 study of QTORIN rapamycin in microcystic lymphatic malformations. The episode closes with company updates, including Sarepta CEO Doug Ingram's retirement and Xenon Pharmaceuticals' upcoming seizure drug readout. *This episode aired on February 27, 2026.

Is what I've been doing for years helpful for achieving autophagy?When you say low carb, do you mean low complex carb or low simple and processed carb?What daily multivitamin would you recommend for a male age 50 plus?Which supplement should I take for elevated triglycerides?

Integrative Healthcare Symposium highlightsWhat supplements can help combat the side effects of cancer therapy?Will my son's use of Zepbound affect his fertility?

In Part 2, Jen shares her coming out story , her switch to the Trio algorithm , surviving a terrifying solo low , and using Zepbound for insulin resistance. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Novo Nordisk announced on Tuesday that it plans to cut the list prices of its blockbuster weight-loss and diabetes drugs Ozempic and Wegovy by up to fifty percent starting January first, twenty twenty-seven. The Danish company stated that various doses of these medications, which contain the active ingredient semaglutide, will drop to six hundred seventy-five dollars per month. This represents a fifty percent reduction for Wegovy and a thirty-five percent cut for Ozempic, with the same price applying to Rybelsus pills. Fox Business reports that Novo Nordisk executive Jamey Millar explained the move aims to help more than one hundred million Americans with obesity and thirty-five million with type two diabetes by lowering out-of-pocket costs, especially for those on high-deductible health plans. CBS News notes this comes amid fierce competition from rivals like Eli Lillys Mounjaro and Zepbound, as well as cheaper compounded versions from telehealth providers. The price slash will align with lower Medicare rates for older Americans but will not affect direct-to-consumer prices, where Wegovy already sells for three hundred forty-nine dollars.In related news, Oprah Winfrey has shared fresh insights on her use of GLP-one medications like those in the Ozempic family. In a recent NBC Connecticut discussion tied to her book Enough, co-authored with Yale Obesity Research Center director Doctor Ania M. Jastreboff, Winfrey reflected on stopping the shots cold turkey on her seventieth birthday in January twenty twenty-four after gaining clarity that obesity drives overeating due to the bodys enough point, a genetically influenced weight set point. She tried maintaining her loss through diet and exercise alone but regained twenty pounds over twelve months, realizing these drugs are a lifelong tool, much like blood pressure medication. Doctor Jastreboff emphasized in the interview that the medications recalibrate this enough point in the brain, reducing hunger signals and fat storage, countering the bodys drive to regain weight. Winfrey, who pays out of pocket for friends unable to afford the shots, urges ending shame around obesity, calling it a disease not a personal failing. She stresses combining drugs with healthy habits for sustainable health, not just looks.These developments highlight growing accessibility and realism around GLP-one drugs amid evolving expert views.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Plus: European lawmakers are considering stopping a vote on a trade deal with the U.S. in light of last week's Supreme Court ruling on tariffs. And Novo Nordisk shares fell sharply after its experimental obesity drug failed to beat out Eli Lilly's Zepbound. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Entering the final trading week of February, Carl Quintanilla, Jim Cramer and David Faber explored what's at stake for the markets, especially after Friday's Supreme Court ruling that struck down many of President Trump's reciprocal tariffs — and the president responding with plans to raise global tariffs by 15%. Shares of Novo Nordisk tumbled: Trial results show its next-generation obesity treatment was less effective than the Eli Lilly drug marketed as Zepbound and Mounjaro. Also in focus: The winter storm blasting the Northeast results in more than 10,000 flight cancellations, Alphabet upgraded, software stocks downgraded, AI roundup, Netflix-Warner latest from Ted Sarandos to Susan Rice and Trump. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

Onze analist van dienst stond al met zijn neus bij de etalage voor een paar aandeeltjes Klarna, toen deze op $30 noteerde. Als een kindje dat pruimen zag hangen, o, als appelen zo groot! Maar wat kan hij in zijn handjes wrijven, want de bodem was voor Klarna nog lang niet in zicht. Na de beursgang in september verloor de Zweedse fintech 70% van haar marktwaarde. Terecht, of is Klarna de kans van de eeuw? En Trump stort beleggers wereldwijd weer in de onzekerheid met zijn heffingenheisa. Goed nieuws voor Azië, waar de nieuwe heffingen lager uitpakken dan de vorige. In het VK zullen ze daarentegen minder staan te springen. Wat is er dit weekend nou precies gebeurd, en wat betekent dat voor jou? Ook daar is genoeg om uit te pakken. Verder in deze show: Box-3 voer voor hoofdredactie Washington Post Netflix bestuurslid moet ONMIDDELIJK ontslagen worden van Trump, terwijl ze middenin de overnamestrijd rond Warner Bros zitten McDonalds is het nieuwe goud Waarom de Zuid-Koreanen dol zijn op hefboompjes VEB wil dat de AFM onderzoek gaat doen naar handel met voorkennis in aandelen van InPost Te gast: Justin Blekemolen van online broker Lynx BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij BNR Zakendoen en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

What if weight loss isn't about discipline—but about biology? In this episode of Healthy Looks Great on You, Dr. Vickie welcomes Dr. Suzanna Chatterjee-Morris, a board-certified OB-GYN and obesity medicine physician, for a fascinating conversation about GLP-1 medications and what they really do inside the body. Together, they take listeners to mini medical school to break down: What GLP-1 medications are and how they affect insulin resistance and metabolism Why weight gain is often a medical issue—not a personal failure How GLP-1s are being used beyond weight loss, including PCOS, infertility, fatty liver disease, sleep apnea, and cardiovascular health What the research shows about long-term benefits and reduced all-cause mortality Common concerns like muscle loss, weight regain, and “Ozempic face” Why nutrition, protein intake, and exercise are essential when using these medications Dr. Chatterjee also explains the concept of weight “set point,” why stopping these medications too soon often leads to regain, and how GLP-1s work best when paired with sustainable lifestyle changes—not willpower alone. If you've been curious or confused about Ozempic, Wegovy, Zepbound, or similar medications, this episode offers clarity, evidence, and reassurance—without hype or shame.

We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity; we also look at the frontier of mental health with synthetic psilocybin; there's phase 3 results from a potential new treatment for chronic inducible hives; and a long-acting HIV injection could be a game-changer for patients who struggle with the daily pill grind.  

I've been sick all week, and it completely disrupted my plans, my workouts, and the momentum I thought I was building.In this episode, I'm talking about what it feels like when your body forces you to rest — and why we often only “allow” ourselves to slow down when we're physically unwell. If you're feeling behind, off track, or like you have to start over, this is your reminder: you're not starting over. You're continuing.Show Notes!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

Send a textWegovy's new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn't which drug helps you lose more weight—it's which one treats your underlying metabolic disease more effectively.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

 Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.comHave you ever wondered which weight loss medication is actually right for you? With so many options out there—new GLP-1 medications like Wegovy and Zepbound, oral versions hitting the market, and older prescriptions—it can feel totally overwhelming.In this episode, we break it all down: how much weight you might realistically lose, how other health conditions factor in, cost considerations, who should avoid certain medications, and even how combination therapy can sometimes make sense.Over the years, I've covered these topics in different ways. One of my favorite episodes was with Dr. Angela Fitch, where we explored all the available medications at that time. Since then, new therapies like Zepbound and oral Wegovy have emerged, changing the landscape even more. This episode isn't meant to replace a one-on-one conversation with an obesity expert—that's still the gold standard—but it gives the information you need to start thinking about what might fit your goals, your body, and your lifestyle.By the end, you'll have a clearer picture of how these medications work, who they help most, and how to approach the decision thoughtfully and safely. Obesity is a medical condition, and like any condition, it deserves expert care—so let's dive into your options.Topics Covered:How Much Weight Can You Really Lose on GLP-1 Medications?The Other Medications That Still Play a Role in Weight LossWegovy vs. Zepbound: How Much Weight Loss Do You Actually Need?Why Weight Loss Is a Struggle—and How the Right Medication Makes the DifferenceResults Matter—But So Does the Price TagWho Should Avoid Certain Weight Loss MedicationsChoosing the Right Weight Loss Medication: Pills, Injections, and Personalized ApproachesDo You Really Need More Weight Loss?By the end of this episode, you'll have a clear understanding of the different weight loss medications, how they work, who they help most, and what to consider when choosing the right approach for your goals and health.For a deeper dive into each medication, real-world results, and expert insights on tailoring a plan that's safe, sustainable, and effective, the full episode is ready for you—it's packed with everything you need to make an informed decision about your weight loss journey.Referenced Episodes:Can a test tell me if Wegovy or Zepbound will work for me? With Dr.Andres Acosta of PhenomixMedications for Weight Loss with guest, Dr. Angela Fitch,Phentermine and Qsymia - What You Need to Know About These Weight LossOral Wegovy: All You Need to Know About This New Medication, with Joseph ZucchiConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Mailbag: Your GLP-1 Questions on Pregnancy, Dosing, and Why Diets Cause Fat GainWhat happens when you stop GLP-1 medications before getting pregnant? Why might your thyroid numbers change on Zepbound? And why do people gain more body fat after dieting — even when they're still eating well? Dr. Cooper tackles your toughest questions.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions covering pregnancy planning on GLP-1s, unmasked thyroid problems, injection site reactions, mechanical eating after bariatric surgery, why diets cause fat regain at a cellular level, and discussing with your doctor whether you should (or shouldn't) increase your medication dose.Key TakeawaysGLP-1 medications aren't causing gestational diabetes — they may have been masking underlying metabolic dysfunction that becomes visible when the medication is stoppedThyroid problems can be "unmasked" by GLP-1 treatment because the medications signal to your brain that you're not starving, allowing the pituitary TSH to rise, sometime uncovering a pre-existing thyroid issueZepbound may improve iron absorption — if iron levels go too high, testing for hemochromatosis may be warrantedTo reduce injection site reactions: warm the medication to room temperature, clean and prep skin but don't over-rub with alcohol, inject at exactly 90 degrees, don't pinch the skin, and stay relaxedDiets cause fat regain at the cellular level — it's chemistry, not willpower — and the fat often accumulates in the visceral area around organsThere's no need to increase your GLP-1 dose if you're making good progress — an annual weight loss rate of 15% or higher is considered strongNotable Quote"You can't think that just because somebody's weight is high, it's because something they're doing is wrong. That is just not founded in science whatsoever." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news and updates on Ozempic, from its medical uses to its effects on lifestyle and health.Ozempic, containing semaglutide, mimics a natural hormone called GLP-1 to release insulin, steady blood sugar, slow digestion, and curb appetite, helping listeners feel full longer. GoodRx reports that studies show people on Ozempic lose six to seven percent of body weight, while Wegovy users average fifteen percent.Recent Cochrane reviews commissioned by the World Health Organization, released February eleventh, twenty twenty-six, confirm GLP-1 drugs like Ozempic deliver meaningful weight loss. Semaglutide leads to about eleven percent reduction after six to seventeen months, with benefits lasting up to two years if continued. Tirzepatide in Mounjaro and Zepbound shows even higher losses around sixteen percent, though more research is needed. Liraglutide offers four to five percent loss.Real-world evidence from Applied Clinical Trials highlights heterogeneous results, typically four to twelve percent loss at six to twelve months. For a twelve percent drop, the drug accounts for sixty-three percent, with context like persistence, lifestyle, and care making up thirty-seven percent. Improving persistence could boost outcomes further.Many hit an Ozempic plateau after twelve months, per GoodRx. Factors include dose, timing, diet, exercise, stress, and other meds like sulfonylureas or antidepressants. Pair it with avoiding fried foods, high-fat items, sugary drinks, and ultra-processed foods for best results.Rutgers Health research in the Journal of Medical Internet Research finds sixty-seven percent of users report weight loss or less appetite despite side effects like nausea, prioritizing effectiveness to keep going. However, stopping leads to regain, though half maintain some loss after a year.Watch for Ozempic face, gauntness from facial fat loss, as noted in a PMC study, so discuss screening and diet with doctors.These updates show Ozempic transforms lives when combined with healthy habits, but long-term independent data is key.Thank you listeners for tuning in. Subscribe for more insights. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commissioned by the World Health Organization analyzed GLP-1 drugs including semaglutide, sold as Ozempic and Wegovy. These studies, drawing from dozens of trials with tens of thousands of participants, show semaglutide leads to an average weight loss of about 11 percent after six to 18 months when paired with diet and exercise. Tirzepatide, marketed as Mounjaro and Zepbound, achieved around 16 percent loss in similar periods. Researchers note these benefits persist during treatment but emphasize limited long-term safety data, common side effects like nausea, and heavy industry funding in most trials. Cochrane reports highlight the need for independent studies on heart health, quality of life, and global access, as high costs limit use in lower-income regions.A Rutgers Health study published this week in the Journal of Medical Internet Research examined why Ozempic users stick with it despite side effects. Analyzing online reviews, researchers found perceived effectiveness in curbing appetite and shedding pounds outweighs issues like stomach upset for most. Lead author Abanoub Armanious noted that everyday users prioritize real results over hype from celebrities or social media. Separately, Weill Cornell Medicine researchers reported on February 11 that GLP-1 drugs like tirzepatide may lower risks of diabetic retinopathy progression in diabetes patients, countering earlier concerns.Oprah Winfrey continues to speak openly about her GLP-1 use, as covered in recent AOL articles. The media icon, who lost about 50 pounds starting in 2023 but regained 20 after briefly stopping, now views these medications as a lifelong tool like blood pressure drugs. Promoting her book Enough, Winfrey shared on The View and her podcast that the drugs silenced constant food thoughts, freeing her from self-blame. She told listeners obesity is not a willpower failure but a brain-driven condition, urging others to seek medical options without shame. Winfrey, who covers costs for friends, also noted reduced alcohol cravings as a bonus.Meanwhile, excitement builds around Eli Lillys oral pill orforglipron, an injectable-free alternative to Ozempic. Phase 3 trials like ATTAIN-1 showed 12.4 percent average weight loss over 72 weeks, with many maintaining results after switching from shots. Walk In reports it could launch in Canada soon, offering daily convenience without fasting, though generics of semaglutide arrive mid-2026 for affordability.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Confira os destaques do Jornal da Manhã desta sexta-feira (13): O ministro Dias Toffoli deixou oficialmente a relatoria do inquérito que investiga as fraudes bilionárias no Banco Master nesta quinta-feira (12). A decisão foi anunciada após uma reunião administrativa de emergência convocada pelo presidente da Corte, Edson Fachin, que contou com a participação de todos os dez ministros. Em nota conjunta, os magistrados negaram a existência de suspeição ou impedimento legal de Toffoli, reafirmando o apoio institucional ao colega, mas informaram que o próprio ministro solicitou a redistribuição dos processos para preservar os “altos interesses institucionais” do tribunal diante do desgaste causado pelas recentes revelações. Para falar sobre o assunto, a Jovem Pan entrevista Gustavo Sampaio, professor de direito constitucional. Nesta quinta-feira (12), o presidente dos Estados Unidos, Donald Trump, afirmou em um post na rede social Truth Social que as relações entre Washington e a Venezuela têm sido “extraordinárias”, elogiando o secretário de Estado Marco Rubio e outros representantes do governo pela condução da política externa naquele país. Trump destacou que o petróleo venezuelano está “começando a fluir” e que grandes quantias de recursos, que não eram vistas há muitos anos, devem ajudar o povo venezuelano em breve. O vice-presidente e ministro da Indústria, Geraldo Alckmin, afirmou nesta quinta-feira (12) que é contra o projeto de lei que prevê a quebra de patentes do Mounjaro e do Zepbound, duas marcas de canetas emagrecedoras. A renúncia de Chris Wormald, secretário de gabinete e um dos principais nomes do governo britânico, aprofundou a crise enfrentada pelo primeiro-ministro Keir Starmer após novas revelações ligadas ao caso Jeffrey Epstein. Wormald se tornou o terceiro integrante da equipe a deixar o cargo em poucos dias. A situação ganhou ainda mais pressão após o nome de Peter Mandelson aparecer em fotos e extratos bancários associados ao escândalo. A Justiça suspendeu liminarmente regras das escolas cívico-militares do estado de São Paulo, sob argumento de que há evidência de violação ao princípio da legalidade, ofensa ao princípio da gestão democrática do ensino e potencial discriminatório. A deputada federal Adriana Ventura (Novo-SP) iniciou a coleta de assinaturas na Câmara dos Deputados para viabilizar a tramitação de uma Proposta de Emenda à Constituição que prevê a obrigatoriedade de códigos formais de conduta e integridade no Judiciário brasileiro. A proposta pretende estabelecer diretrizes éticas para ministros do STF e de outros tribunais superiores, ampliando mecanismos de controle e transparência institucional. O Governo de São Paulo lançou um alerta à população sobre os riscos do consumo de bebidas alcoólicas adulteradas durante o Carnaval. A campanha reforça a importância de comprar apenas em estabelecimentos regularizados, verificar a procedência dos produtos e evitar itens de origem desconhecida. Segundo o Centro de Vigilância Sanitária de São Paulo, ações de fiscalização serão intensificadas em parceria com vigilâncias municipais, responsáveis pela inspeção de comércios e vendedores ambulantes. Nesta sexta-feira (13), primeira noite do Carnaval em São Paulo, a Mocidade Unida da Mooca, estreante no grupo especial, abre os desfiles a partir das 23h, enquanto a Barroca Zona Sul será a última a entrar no sambódromo, com início previsto para as 5h30 de sábado (14). Ao todo, serão sete escolas na sexta e mais sete no sábado; das 14 agremiações que participam neste fim de semana, duas serão rebaixadas após a apuração das notas marcada para as 16h de terça-feira (17). Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Lately, the world is heavy. Overwhelming. At times, even unsafe. And I'll be honest, it's been hard to show up and talk about things like body image, weight, or self-care when everything around us feels so serious.But then I watched the Super Bowl halftime show and Bad Bunny showing up boldly, joyfully, unapologetically, and it brought me back to a quote that stopped me in my tracks: joy is part of the resistance.In this episode, I'm sharing a very real moment of burnout. One where I was so overwhelmed I would've rather gone to the emergency room than keep dealing with life, even though nothing was physically wrong. We talk about the kind of society we're living in, where people secretly wish for a stomach virus just to get a break, and what it means when rest only feels allowed through sickness.I share why a glow up has shifted from nice-to-have to need-to-have — focusing first on the inside, not the outside — and how choosing movement, care, joy, and self-respect isn't avoidance, it's survival.If you feel exhausted, overwhelmed, and weighed down by the world around you, this episode is for you.

Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly's earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Em uma votação que uniu praticamente todos os partidos, do PL ao PT, a Câmara dos Deputados aprovou a urgência para o Projeto de Lei que declara os medicamentos Mounjaro e Zepbound (à base de tirzepatida) como de "interesse público".A medida, proposta pelo deputado Dr. Mário Heringer (PDT-MG), abre caminho para o licenciamento compulsório — a famosa quebra de patente — visando baratear o acesso às canetas emagrecedoras, consideradas por muitos parlamentares uma ferramenta essencial de saúde pública contra a obesidade.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Introduction — Are GLP-1 Drugs Forever?Have you heard experts say that GLP-1 medications like Ozempic, Wegovy, or Zepbound are forever drugs — because once you stop, you regain all the weight?I'm not fully convinced that's true.I've found three promising approaches being developed that may help people stop medication without immediate weight regain.Each approach is completely different:One focuses on the stomachOne on the brainOne on structured lifestyle interventionI'm Dr. Gary Pepper. I've practiced endocrinology for over 30 years. This podcast is unsponsored, and I receive no financial compensation from the treatments discussed. This content is educational only and not a substitute for medical care from your physician.Chapter 1 — Resetting the Gut (DMR)The first approach is called Duodenal Mucosal Resurfacing (DMR).The theory is that while you're on GLP-1 medication, the part of the stomach that normally produces appetite-regulating hormones becomes dormant. After long enough, it may struggle to restart when medication stops.DMR removes the top layer of the stomach lining using a heated endoscope. This forces regeneration of fresh cells that produce appetite-controlling hormones.In a short three-month study, patients who underwent the procedure did not regain weight after stopping medication — some continued to lose.This sounds dramatic, but the technique is already FDA-approved for other stomach conditions. It is not yet approved for weight management, but it shows where research is heading.Chapter 2 — Retraining the Brain (rTMS)The second approach targets the brain instead of the gut.It's called Transcranial Magnetic Stimulation (rTMS) — already used for depression treatment.Magnetic coils stimulate appetite control centers in the brain. After just five weeks of treatment, participants lost as much weight over a year as those taking semaglutide for a full year.This is early research, but it suggests appetite control may eventually be trained neurologically rather than chemically.Chapter 3 — Exercise as Hormone RehabilitationThe third approach is the most practical and immediately available: structured exercise.Researchers at the University of Copenhagen studied people stopping GLP-1 medication after a year of use.Those who followed a structured program of resistance and cardio training regained almost no weight — averaging about five pounds over a year.Those returning to sedentary habits regained most of their weight.Exercise appeared to restore the body's natural GLP-1-like hormone production.This is not about willpower.It's biological rehabilitation.Closing — A Changing LandscapeThese three approaches show that weight regain after GLP-1 is not inevitable.The science is evolving quickly.I'll continue tracking new developments and sharing updates here.Thanks for listeninGary Pepper, M.D., an associate professor at a prominent medical school and endocrinologist with 40 years of experience, brings clarity to numerous topics within the field of metabolic health. His view points are unhindered by corporate interests, unlike many other current "thought leaders" in medicine. Dr. Pepper, a dedicated educator, established his homebase website www.metabolism.com in 1996 and has blogged on important topics since then. Not one to be left behind by technology he began podcasting in 2020 with the onset of the pandemic and continues publishing vlogs on YouTube at his channel metabolism123. So whatever your choice in media, you will be gaining fresh insights by tuning in to his opinionated shows or reading his blogs on critical health topics.

Grâce à une fiscalité avantageuse, l'Irlande a su attirer les géants pharmaceutiques, au point d'en faire l'un des piliers de son économie. Mais Donald Trump brandit désormais la menace de droits de douane, pour pousser ces entreprises à relocaliser aux Etats-Unis. Or, les médicaments représentent près de la moitié des exportations irlandaises, avec les États-Unis comme premier client ! En Europe, l'Irlande serait ainsi le pays le plus exposé. Près de Cork, Ringaskiddy, surnommé le « village du Viagra », retient son souffle. Reportage de Clémence Pénard. John n'avait que 22 ans quand Pfizer s'est installé à Ringaskiddy. C'était en 1969 : « Tu vois, juste là, le château d'eau ? L'espèce de champignon, là ! Ça appartient à Pfizer !  » Le succès est tel que l'entreprise s'empresse de construire deux autres usines. Si bien qu'aujourd'hui, sous les coups de 8 heures, le site devient une véritable fourmilière : « Le matin, les routes sont totalement saturées : les files de voitures s'étendent sur des kilomètres. Et c'est la même chose le soir ! Une autoroute devait être construite il y a trente ans… Bon, elle doit être terminée d'ici trois ans. On vit dans l'espoir ! » Le « Pfizer Stop » Un arrêt de bus, le « Pfizer Stop », a tout de même été créé, rien que pour les salariés qui produisent, depuis 1998, le médicament le plus tonique de la région : le viagra !  « À l'époque, on n'arrivait même pas à prononcer le nom : "Pf i zeur" ! Mais tout le monde voulait y travailler, absolument tout le monde. Les salaires étaient multipliés par quatre ! Même le fournisseur de papier toilette était devenu riche ! » Et il n'a pas fallu longtemps pour que le « village du Viagra » attire d'autres géants pharmaceutiques. Aujourd'hui, les Américains Johnson & Johnson, Thermo Fisher ou encore BioMarin profitent eux aussi du port de cet ancien village de pêcheurs, idéal pour exporter leurs médicaments !  Et à seulement 20 km de là, Lilly fabrique Mounjaro et Zepbound, deux médicaments anti-obésité, best-sellers aux États-Unis !  Ambiance à Ringaskiddy et dans les villages voisins Ainsi, dans Ringaskiddy et les villages voisins, ce sont plus de 20 000 personnes qui travaillent pour ces mastodontes, souvent de génération en génération. Audrey Buckley est élue locale du Fianna Fáil, le parti au pouvoir : « S'il arrivait quoi que ce soit à l'industrie pharmaceutique ici, ce serait tout simplement dévastateur pour toute la région. Dévastateur… Aujourd'hui, au dîner autour de la table, les mêmes questions reviennent sans cesse : est-ce que tels travaux ont démarré à l'usine? Est-ce qu'il y a de nouveaux projets ? Or, tout semble à l'arrêt. C'est une énorme source d'angoisse, les gens repoussent l'achat d'une voiture, l'extension de la maison, et ainsi de suite. Ils dépensent moins, c'est sûr, donc on voit déjà des effets ! »  Économiste à l'université de Cork, Eleanor Doyle voit aussi un ralentissement du secteur, mais tente tout de même de rassurer : « Pour les usines pharmaceutiques, les délais pour obtenir les autorisations de construction sont si longs, qu'à moyen terme, une délocalisation est peu envisageable ! » Pour l'instant, l'Irlande profite d'un répit, l'administration américaine semblant se concentrer sur d'autres régions du monde.

United States Attorney General Pam Bondi discusses the custody of a key participant in the 2012 Benghazi attack, which killed four Americans. The family of Savannah Guthrie's mother appeals to the public for information as the emotional toll of her disappearance grows. Authorities have provided updates on the search, and Mark offers a breakdown of the situation. Mark takes your calls!  Mark interviews plastic surgeon Dr. Arthur Perry. They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions.

They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions.See omnystudio.com/listener for privacy information.

United States Attorney General Pam Bondi discusses the custody of a key participant in the 2012 Benghazi attack, which killed four Americans. The family of Savannah Guthrie's mother appeals to the public for information as the emotional toll of her disappearance grows. Authorities have provided updates on the search, and Mark offers a breakdown of the situation. Mark interviews plastic surgeon Dr. Arthur Perry. They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions. Did Senator Elizabeth Warren give Treasury Secretary Scott Bessent a supportive gesture during recent testimony about the nation's financial health? Minority Leader Chuck Schumer continues to oppose voter ID requirements, arguing that they would disenfranchise immigrants and likening the policy to a return to similar Jim Crow laws from the 1900's. Mark interviews author Mark Malkoff. Their conversation centers on Johnny Carson's legacy of making stars of his guests and on speculation about the future of late-night television, with Malkoff predicting its potential end depending on changes in the broadcasting landscape.

They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions.

United States Attorney General Pam Bondi discusses the custody of a key participant in the 2012 Benghazi attack, which killed four Americans. The family of Savannah Guthrie's mother appeals to the public for information as the emotional toll of her disappearance grows. Authorities have provided updates on the search, and Mark offers a breakdown of the situation. Mark interviews plastic surgeon Dr. Arthur Perry. They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions. Did Senator Elizabeth Warren give Treasury Secretary Scott Bessent a supportive gesture during recent testimony about the nation's financial health? Minority Leader Chuck Schumer continues to oppose voter ID requirements, arguing that they would disenfranchise immigrants and likening the policy to a return to similar Jim Crow laws from the 1900's. Mark interviews author Mark Malkoff. Their conversation centers on Johnny Carson's legacy of making stars of his guests and on speculation about the future of late-night television, with Malkoff predicting its potential end depending on changes in the broadcasting landscape. See omnystudio.com/listener for privacy information.

United States Attorney General Pam Bondi discusses the custody of a key participant in the 2012 Benghazi attack, which killed four Americans. The family of Savannah Guthrie's mother appeals to the public for information as the emotional toll of her disappearance grows. Authorities have provided updates on the search, and Mark offers a breakdown of the situation. Mark takes your calls!  Mark interviews plastic surgeon Dr. Arthur Perry. They discuss various cosmetic procedures, the effectiveness of drugs like Ozempic and ZepBound, and address issues such as sagging skin caused by these medications, along with solutions. See omnystudio.com/listener for privacy information.

TrumpRX is President Donald Trump’s newly launched direct‑to‑consumer prescription drug platform, designed to offer steep cash‑pay discounts on brand‑name medications through Most-Favored‑Nation (MFN) pricing deals with major pharmaceutical companies. The site lists 40+ discounted drugs, including Ozempic, Wegovy, Zepbound and common fertility medications, sometimes slashing prices from over $1,000 to under $350 for cash-paying patients. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | InstagramSee omnystudio.com/listener for privacy information.

PODCAST LAS NOTICIAS CON CALLE DE 5 FEBRERO DE 2026 -  Frío tan bestial que en Cuba se reportan temperaturas de 32 grados - Weather Culpable AudriNix Militares siguen contratando alquileres en PR, quieren más del aeropuerto de Ceiba y Aguadilla - El Nuevo Día Madre deja hijos en cuartel de la policía porque no puede con las complicaciones de la maternidad - WUNOLa Junta detiene contrato de generación temporera de Power Expectations en Aguirre - El Nuevo Día Querella contra Eliezer Molina por supuestamente discriminar contra una empresa de origen judío - El Nuevo Día Wanda tendrá que hablarle al Supremo en 9 días para ver si perdió el título o no - El Nuevo Día Haitianos deportados que han sido asesinados siguen aumentando - El Nuevo Día Aumentan referidos por casos de maltrato de menores - El Nuevo Día Viene hotel en lo que era Lote 23 - El Nuevo Día Buscan cambiar los arbitrios de carros en PR - El Nuevo Día En crisis las crypto, cayendo a casi la mitad de lo que valían - Bloomberg Lilly vendió 110% más mounjaro y Zepbound 122% más que el año pasado - Axios Xi le reclamó a Trump por venta de armas a Taiwán - Reuters Constructores dicen que no los han invitado a participar de proceso de permisos - El Nuevo Día Estados Unidos reconoce que bombardeó a ISIS en Syria este weekend pasado tras confrontación en Palmyra - Bloomberg Querellas contra maestros y otros casi no se mueven en Educación - Metro Hacienda todavía no tiene fecha de entrega de info a Legislatura - Metro 1466 casos de maltrato en Familia denunciados en un mes - El Vocero Alcalde de Isabela usa escuelas abandonadas y rescata 8 de 10 escuelas - El Vocero Casi todos los agentes desarmados siguen trabajando en la policía, pero como administrativos - Primera HoraViene más lluvia para el weekend - Meteorología - Primera HoraPR va a jugar en el Clásico tras amenaza de que no jugarían - Primera HoraPIP pide declaración de emergencia por maltrato de menores - WAPA • ¿Quieres ser un líder empresarial? • Con el Bachillerato en Administración de Empresas con concentración en Gerencia de EDP University, te capacitas para liderar y tomar decisiones clave en cualquier organización. • Desarrollarás habilidades en gerencia, finanzas, mercadeo y recursos humanos, ¡e incluso aprenderás a crear y lanzar nuevos negocios! • Conviértete en el gerente innovador y estratégico que la empresa necesita. • Disponible 100% en línea, presencial en Hato Rey y Humacao.• No esperes más, y ¡matricúlate! en EDP University, Saber es PoderIncluye auspicio 

Send us a textThis week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originally had the market lead. He talks about how Eli Lilly capitalized on competitor weaknesses through Zepbound and Mounjaro. One warning from Matt: "don't be afraid to buy both stocks," just do it through nibbles. He points to Eli Lilly's substantial P/E ratio and Novo Nordisk's anemic metric. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Send us a textThis week on On The Pen: The Weekly Dose, we break down Pfizer's $10 billion bet on obesity medicine and whether it's shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer's once-monthly GLP-1 candidate (formerly Metsera's asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies. We also talk strategy, maintenance dosing, combination GLP-1 + amylin approaches, pricing pressures, cash-pay access, and what this all means for patients navigating a rapidly changing obesity treatment landscape. Plus, earnings week insights, where Pfizer may be headed next, and why pricing and access, not just weight-loss percentages, may end up being the real disruptors.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Mazel Morons! Oh boy, do we have a treat for you this week. Drake Bell is back on the show and immediately thrown into the madness: Josh's flu-voice, Ben's missing ass (as confirmed by Zepbound), and a deeply emotional discussion about… toddler pooping anxiety. We catch up on Drake's wild year - 91 shows, 150 flights, Latin America tours, dad life in Florida, Minions Land obsessions - and Drake tells the full story of the absolutely deranged reality show that made him dive off a 33-foot platform and burst his eardrum.We also get into parenting philosophies, routines, gambling responsibly (we think), dermatology fears, how becoming fathers changed everything, and whether the trio has officially entered their “unc” era. It's nostalgic, hilarious, heartfelt, and exactly the kind of episode fans loved the last time Drake joined the show.Leave us a voicemail here!Follow us on Instagram and TikTok! Sponsors:As a special offer for GOOD GUYS listeners, goodwipes is giving you your first pack for FREE! Buy any package in store, text them your receipt, and get reimbursed almost immediately. For more details, head to goodwipes.com/GOODGUYS. See thicker, stronger, faster-growing hair with less shedding in just 3-6 months with Nutrafol. For a limited time, Nutrafol is offering our listeners $10 off your first month's subscription and free shipping when you go to Nutrafol.com and enter the promo code GOODGUYS10Right now, Collective is giving you fifty percent off of your first two months when you go to Collective.com/GOODGUYSShop SKIMS Mens at http://www.skims.com/goodguys #skimspartnerHead to Superpower.com and use code GOODGUYS at checkout for $20 off your membership. Live up to your 100-Year potential. #superpowerpodPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. What happens when the medication that's finally helping you is no longer affordable?If you've had success on Mounjaro or Zepbound but need to switch to a more affordable option like Ozempic for maintenance, you're probably wondering: will this actually work? And if semaglutide didn't help you before, the idea of going back can feel risky, especially when you're worried about regaining weight, increased food noise, or losing the progress you've worked so hard for.In this episode, I break down when switching medications for cost makes sense, when it's likely to backfire, and what your options are if semaglutide is the only affordable option. Referenceshttps://www.orchardpond.com/The 30/30 Program (Sept 2026 registration now open)Audio Stamps01:08 - Update on Dr. Rentea's retreat planning, plus her new favorite granola discovery.05:03 -  Listener question: Switching from Mounjaro to Ozempic for long-term maintenance due to cost.05:59 - When it makes sense to switch medications for affordability (and when it doesn't).08:03 -  If semaglutide is your only option: combining GLP-1s with oral medications.10:48 - Oral (daily) Wegovy vs injections: does steadier dosing actually help?11:40 - Why no medication is perfect and working with the right clinician is key.12:58 - The real reason behind this work: preventing disease, not chasing a number on the scale.14:05 - September 30/30 program update: early registration + monthly Q&A access.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Dr. Natalie Crawford, board-certified OB-GYN and REI, answers your fertility questions. Questions Answered: 1. A 30-year-old in a same-sex couple with anovulatory PCOS managed on metformin, high AMH, and otherwise normal labs moved from failed IUIs to IVF and had 19 mature eggs but only 4 fertilized despite good donor sperm—what could explain low fertilization rates and how should the next steps be approached? 2. 35 and trying for baby number two, and her 40-year-old husband has been on the GLP-1 medication Zepbound for four months—are there known effects of GLP-1s on male fertility, and should men discontinue them while trying to conceive? 3. A patient with PCOS and mildly elevated thyroid levels is experiencing medication interactions and was prescribed 2.5 mg of methylfolate— is this dose appropriate, and should she be taking methylfolate, folic acid, or both? 4. A patient with endometriosis underwent two egg retrievals, one with estrogen priming that triggered an endometriosis flare and resulted in very high estrogen levels and poor egg maturity—are there stimulation protocols better suited for patients with endometriosis undergoing IVF? 5. A 38-year-old planning IUI with donor sperm, normal fertility workup, AMH of 3.3, and a personal history of being a twin is deciding between natural versus medicated cycles— which approach is more successful while minimizing twin risk and preserving future fertility goals? Pre-order Dr. Crawford's debut book, The Fertility Formula, now! ⁠⁠⁠https://www.nataliecrawfordmd.com/book⁠⁠⁠ Want your questions answered on the next episode? ⁠Ask them here!⁠ ⁠https://www.nataliecrawfordmd.com/qa-submissions⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices